CVP

An option for first-line or subsequent treatment of CLL, follicular and other indolent NHL Aggressive cases of NHL not suitable for anthracycline based regimens

Drugs / Dosage: Cyclophosphamide 750mg/m² IV Day 1

Vincristine 1.4mg/m² (max 2mg) IV Day 1

Prednisolone 100mg (fixed dose) PO Days 1, 2, 3, 4 and 5

Age > 60 yrs and pre-existing constipation or neurological problems, consider

vincristine dose of 1mg. If in doubt, check with Consultant.

Administration: Vincristine administered via fast running infusion of 0.9% Sodium Chloride

Cyclophosphamide given as a bolus

Other Drugs: Allopurinol 300mg po daily, ideally starting 24 hours before chemotherapy –

review after 3 weeks

Use of proton pump inhibitor or H₂ receptor antagonist (e.g. ranitidine) is

recommended whilst treating with steroids.

Frequency: 3 weekly cycle

Stage IA NHL: 3-4 cycles, with IF radiotherapy

Stage II – IV NHL: Treat to CR or maximum response plus 2 more cycles, for a

minimum of 6 cycles and a maximum of 8 cycles

Main Toxicities: myelosuppression; alopecia; mucositis; haemorrhagic cystitis;

peripheral neuropathy; constipation; ovarian failure; infertility

Anti – emetics: Moderately emetogenic (but oral dexamethasone not needed due to prednisolone;

dexamethasone iv is optional)

Extravasation: Vincristine is a vesicant

Regular FBC Day 1 Investigations: LFT Day 1

U&Es Day 1 LDH Day 1

Dose Modifications

Haematological If neutrophils $< 1.0 \times 10^9 / 1$ or platelets $< 100 \times 10^9 / 1$ on Day 1, delay

Toxicity: chemotherapy until FBC recovered, then continue with 20% dose reduction of

cyclophosphamide

If low counts are due to marrow infiltration, discuss with Consultant.

Reason for Update: Prepared for Network use	Approved by Chair of Network TSSG: Dr A Laurie
Version: 1	Date: 9.2.06
Supersedes: All previous versions	Review date: February 2008
Prepared by Oncology Pharmacist: S Taylor	Checked by Network Pharmacist: Jacky Turner

Surrey, West Sussex and Hampshire Cancer Network NHS

Renal Impairment:

If serum creatinine above normal range, estimate creatinine clearance using Cockcroft & Gault and dose cyclophosphamide accordingly.

CrCl (ml/min)	Cyclophosphamide Dose	
> 50	Give 100%	
10 – 50	Give 75%	
< 10	Give 50%	

Hepatic Impairment:

Bilirubin (μmol/l)	ALT / AST (units/l)	Vincristine Dose
26 - 51	or	60 - 180	Give 50%
> 51	and	Normal	Give 50%
> 51	and	> 180	Omit

Neurotoxicity:

Give 50% vincristine dose if Grade 2 motor and/or Grade 3 sensory toxicity

If in doubt, discuss with Consultant.

Patient Information: CancerBACUP leaflets for Cyclophosphamide and Vincristine

Reference: Rosenberg, S.A.; JCO (1985); 3: 299 – 310

Reason for Update: Prepared for Network use	Approved by Chair of Network TSSG: Dr A Laurie
Version: 1	Date: 9.2.06
Supersedes: All previous versions	Review date: February 2008
Prepared by Oncology Pharmacist: S Taylor	Checked by Network Pharmacist: Jacky Turner